Riociguat Oral Tablet

DRUG2 trials

Sponsors

National Hospital Organization Okayama Medical Center, Heidelberg University

Conditions

Hypertension, PulmonaryOther Systemic Involvement of Connective TissuePrimary Pulmonary HypertensionPulmonary Vascular DisorderSystemic Sclerosis

Phase 2

THERAPY-HYBRID-BPA Trial

National Hospital Organization Okayama Medical CenterHypertension, Pulmonary

Start: 2020-10-16End: 2025-01-28Target: 72Updated: 2020-10-23

Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH

TerminatedNCT05339087

Heidelberg UniversityOther Systemic Involvement of Connective Tissue, Primary Pulmonary Hypertension, Pulmonary Vascular Disorder +1

Start: 2022-10-24End: 2025-07-31Updated: 2026-01-21

Related Papers

Efficacy and safety of riociguat in early pulmonary vascular disease (ESRA): a prospective, multicenter, randomized, double-blind, placebo-controlled phase IIa trial.

2026-07-15

Effect of riociguat on exercise following balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension in Japan (THERAPY-HYBRID-BPA): a multicentre, double-blind, randomised, controlled, phase 4 trial.

2025-07-232 citations

Protocol for a multicentre, double-blind, randomised, placebo-controlled trial of riociguat on peak cardiac index during exercise in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty (THERAPY-HYBRID-BPA trial)

BMJ Open2023-07-017 citations